Next Article in Journal
Task-Irrelevant Features in Visual Working Memory Influence Covert Attention: Evidence from a Partial Report Task
Previous Article in Journal
Inhibitory and Facilitatory Cueing Effects: Competition between Exogenous and Endogenous Mechanisms
Open AccessArticle

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients

1
Novartis Pharma AG, 4002 Basel, Switzerland
2
Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 2145, Australia
3
IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany
*
Author to whom correspondence should be addressed.
Vision 2019, 3(3), 41; https://doi.org/10.3390/vision3030041
Received: 4 July 2019 / Revised: 7 August 2019 / Accepted: 21 August 2019 / Published: 26 August 2019
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented. This retrospective, non-comparative, non-randomised study of eyes with nAMD classified treatment interval sequences in a T&E cohort in Australia using Electronic Medical Records (EMR) data. We analysed data from 632 treatment-naïve eyes from 555 patients injected with ranibizumab, aflibercept or unlicensed bevacizumab between January 2012 and June 2016 (mean baseline age 78.0). Eyes were categorised into non-overlapping clusters of interval sequences based on the first 12 months of follow-up. We identified 523 different treatment interval sequences. The largest cluster of 197 (31.5%) eyes attained an 8-week treatment interval before dropping to a shorter frequency, followed by 168 (26.8%) eyes that did not reach or attained a single 8-week interval at the end of the study period. A total of 65 (10.4%) and 83 (13.3%) eyes reached and sustained (≥2 consecutive injection intervals of the same length) an 8 and 12 weekly interval, respectively. This study demonstrates highly individualised treatment patterns in the first year of anti-VEGF therapy in Australia using T&E regimens, with the majority of patients requiring more frequent injections than once every 8 weeks. View Full-Text
Keywords: nAMD; anti-VEGF; unlicensed bevacizumab; aflibercept; ranibizumab; age-related macular degeneration; treat and extend nAMD; anti-VEGF; unlicensed bevacizumab; aflibercept; ranibizumab; age-related macular degeneration; treat and extend
Show Figures

Figure 1

MDPI and ACS Style

Skelly, A.; Bezlyak, V.; Liew, G.; Kap, E.; Sagkriotis, A. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision 2019, 3, 41. https://doi.org/10.3390/vision3030041

AMA Style

Skelly A, Bezlyak V, Liew G, Kap E, Sagkriotis A. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision. 2019; 3(3):41. https://doi.org/10.3390/vision3030041

Chicago/Turabian Style

Skelly, Adrian; Bezlyak, Vladimir; Liew, Gerald; Kap, Elisabeth; Sagkriotis, Alexandros. 2019. "Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients" Vision 3, no. 3: 41. https://doi.org/10.3390/vision3030041

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop